Jan specializes in the formation of alliances between public and private sectors for the purpose of enhancing the effectiveness and cost efficiency of their projects and messages. She has worked with K2 Communications on a free lance basis for the past 16 years to secure and manage partnerships for numerous television and movie projects, including IMAX fi lms. She secured the title sponsor for Everest, the highest grossing large format film in history, and executive produced Adventures in Wild California, Fighter Pilot and two new films to be released in 2010, Legends of Flight and Rescue.

Previously, Jan held executive positions in corporate and non-profit organizations, overseeing public policy, research and development, and raising millions of dollars for a wide range of causes.

Jan is a graduate of the University of Southern California as well as the Institute for Organizational Management at Stanford University

In February 2009, Adriane M. Brown was named "One of the 100 Most Powerful Executives in Corporate America" by Black Enterprise magazine, a monthly publication that provides 4.3 million readers with information on entrepreneurship, careers and financial management.

From January 2005 until August 2009, Brown served as President and CEO of Honeywell Transportation Systems. Headquartered in Torrance, California, Honeywell Transportation Systems generated annual revenue of $5 billion and consists of three automotive-related businesses: Turbo Technologies; Consumer Products Group and Friction Materials. Turbo Technologies is recognized around the world as a leading innovator in turbochargers, which improve vehicle performance, fuel economy and emissions. Consumer Products Group manufactures and markets a host of leading automotive consumer branded products, including FRAM filters, Prestone antifreeze, Autolite spark plugs, and Holts car care products. Friction Materials is a global supplier of automotive brake friction materials and aftermarket brake products under the Bendix and Jurid brands.

Brown served as Vice President and General Manager of Honeywell Engine Systems & Accessories from September 2001 to January 2005. She joined Honeywell in 1999 as Vice President and General Manager of Aircraft Landing Systems. Prior to that, she spent 19 years at Corning, Inc. In January 1999, she was appointed Vice President and General Manager of the Environmental Products Division, leading Corning's global automotive business. Prior to that, she held numerous positions of increasing responsibility in manufacturing, sales, business development and general management.

Brown earned her Bachelor's degree in Environmental Health from Old Dominion University and Master's degree in Management, as a Sloan Fellow, from Massachusetts Institute of Technology.

She currently serves on the Board of Directors of Jobs for America's Graduates, one of the nation premier drop out prevention programs, and is a member of the Executive Leadership Council.

Taco Bell is the nation's leading Mexican-style quick service restaurant chain with more than $6 billion in annual system-wide sales. As head of Taco Bell, Greg brings a proven track record of more than 25 years experience in marketing and operations with leading packaged goods and restaurant brands.

Most recently, Greg served as YUM Chief Operating Officer, where he initiated and launched a one-system people approach across our entire global operations by working with COOs and their teams. He also led the strategy development and expansion for Taco Bell International.

Greg was Chief Marketing Officer at Taco Bell during its highest sales and transaction growth period in recent history, where he spearheaded the “Think Outside the Bun” marketing efforts and new product introductions that generated consistent same store sales and profit growth during the last five years.

Greg joined Taco Bell Corp. in May 2001, after having served as Chief Marketing Officer for Tricon Restaurants International (TRI) and developing the Taco Bell brand in Australia. He was also instrumental in delivering record KFC sales growth year over year for three consecutive years before coming to Taco Bell Corp. Greg joined PepsiCo in 1994 as Director of Marketing for KFC in Australia and has established a reputation as an innovative and energetic marketer - both in the U.S. and internationally.

When TRI was formed in 1997, Greg was given the extra responsibility of Pizza Hut marketing and he later became the General Manager of Taco Bell and Chief Marketing Officer for all three brands. Previously, Greg was at Unilever for 17 years and during his post was stationed in Australia, London and New York where he ran brands such as Dove, Wisk, Surf and All.

Greg received a bachelor's degree in marketing from Queensland University of Technology in Australia.

Mr. Oberman has litigated a wide variety of complex civil cases at the trial and appellate levels and in arbitration, including antitrust, breach of contract, copyright, securities and trademark cases. Mr. Oberman recently served as lead trial counsel for the respondent in a 20-day arbitration, which resulted in a complete victory for our client. Mr. Oberman obtained injunctive relief on behalf of a publisher of video games in a landmark decision providing expansive copyright protection for video games. In another case, he obtained a judgment dismissing a claim for $100 million in consequential damages. In addition to litigating intellectual property law cases, Mr. Oberman counsels clients on copyright and trademark law.

Mr. Oberman heads the firm's Alternative Dispute Resolution Practice Group. His experience in alternative dispute resolution proceedings includes service as an arbitrator and a mediator. In addition to regularly practicing in the federal and state courts, Mr. Oberman has written on court procedures and administration and is active in efforts for court reform. He has served as a member of Chief Judge Kaye's Commercial Courts Task Force, which created the Commercial Division of the New York Supreme Court. Mr. Oberman also served as a member of the Advisory Committee on Second Circuit Rules and Operating Procedures, and has served since 1989 as a member of the Executive Committee of the Commercial & Federal Litigation Section of the New York Bar Association. Mr. Oberman is listed in New York Super Lawyers for 2006, 2007, 2008 and 2009, and within the 2008 and 2009 Super Lawyers Corporate Counsel edition.

Dr. O'Connor received his Ph.D. from the NYU School of Medicine in Biochemical Toxicology and Chemical Carcinogenesis, and his M.D. from UMDNJ. He then went on to complete a medical internship and residency at The New York Hospital-Cornell University Medical Center.

Following his medical residency, he completed a fellowship in Medical Oncology at the Memorial Sloan Kettering Cancer Center, where he was Chief Fellow from 1997-1998, and a Fellowship in Clinical Pharmacology at the New York Hospital-Cornell University Medical School. He completed a post-doctoral fellowship in the laboratory of Dr. Joseph R. Bertino developing hematopoietic stem cell gene transfer protocols using mutant drug resistance genes. He remained on faculty at Memorial Sloan Kettering from 2000 to 2007 as an Attending Physician in the Department of Medicine on the Lymphoma Service, and Head of the Laboratory of Experimental Therapeutics for the Lymphoproliferative Malignancies at Memorial Sloan Kettering Cancer Center. In 2007 he was appointed the Director of the Lymphoid Development and Malignancy Program in the Herbert Irving Comprehensive Cancer Center at Columbia University, and Chief of the Lymphoma Service in the College of Physicians and Surgeons at The New York Presbyterian Hospital at Columbia University Medical Center. He was recently appointed Professor of Medicine and Pharmacology, and the Deputy Director of the NYU Cancer Institute for Clinical Research and Cancer Treatment, and Chief of the Division of Hematologic Malignancies and Medical Oncology, in the Department of Medicine at NYU Langone Medical Center.

Dr. O'Connor maintains a laboratory program focused on the discovery and development of novel small molecules for the treatment of non-Hodgkin's lymphoma and Hodgkin's lymphoma using unique animal models of these diseases and high-throughput screening approaches. Clinically, he conducts Phase I and II clinical trials, with an emphasis on pharmacokinetic and pharmacodynamic studies. He has a particular interest in the development of proteasome inhibitors, epigenetic therapies and Bcl-2 targeted drugs for the treatment of lymphoproliferative malignancies. To date, his efforts in the laboratory and clinical research have led to the FDA approval of Bortezomib (Velcade), SAHA (Vorinostat) and Pralatrexate for the treatment of mantle cell and T-cell lymphoma.   (cont)

Dr. O'Connor is a member of several professional societies, including the American Association for Cancer Research, the American Society for Clinical Oncology, the American Society of Clinical Pharmacology and Therapeutics, and the American Society for Hematology. He serves on the Lymphoma and Pharmacology and Experimental Therapeutics (PET) Committees for the CALGB. He was a founding member of the Executive Committee for the Mantle Cell Lymphoma Consortium for the Lymphoma Research Foundation (LRF), and serves as a member of their Scientific Advisory Board. He is a Senior Editor for Clinical Cancer Research, and is also on the Editorial Board for the Journal of Clinical Oncology and Leukemia and Lymphoma. He has published nearly 100 articles in numerous journals, including Proceedings of the National Academy of Science, Journal of Clinical Oncology, Blood, Clinical Cancer Research, British Journal of Hematology, Leukemia and Lymphoma, Environmental Science and Technology and Environmental Toxicology and Chemistry. Dr. O'Connor is the recipient of several honors and awards, including the Scholar in Clinical Research Award from the Leukemia and Lymphoma Society, a Merit Award from the American Society for Clinical Oncology, the William Guy Forbeck Scholar Award, and co-recipient of the Ellen Glesby Cohen Leadership Award from the LRF for his contributions to mantle cell lymphoma.

Honeywell Aerospace – Torrance is recognized as a leading innovator in Environmental Control Systems and related products for commercial and military aerospace. Its Center of Engineering Excellence, Research and Production Development, and Integrated Supply Chain drive annual sales of $370M.

Pam has held leadership positions with Honeywell in Contracts / Program Management and Quality. Before joining Honeywell, Pam's diversified background included numerous positions in Procurement and Business Management. She is also a California Credentialed Teacher.

Pam earned her Bachelor's degree from California State University, Long Beach and a Master of Business Administration from the University of Phoenix. She is a Senior Member of American Society for Quality and a certified Six Sigma Black Belt.

In 1984, I had the pleasure of watching the birth of my first child, Alese. It was amazing to witness her take her first breaths and listening to the little noises and cooing this contented little baby made during her first minutes of life. Twenty-three years later, I had the horrific experience of witnessing her take her last breath as her time on earth expired. This event is so painful and sorrowful that I cannot fully put it into words. It’s something I wish no parent would ever have to endure.

During the five and a half years Alese battled Hodgkin’s disease, we met many, many doctors and in December 2004, Alese moved to the East Coast to be under the care of Sloan Kettering’s, Dr. Owen O’Connor. Dr. O’Connor is internationally recognized and is one of the top two lymphoma researchers in the country. The day after Alese died, Dr. O’Connor called Kathy and presented the idea for this campaign. To Alese, Dr. O’Connor was more than just a doctor, he was her friend.

Throughout her illness, Alese always made herself available to other Hodgkin’s patients. She was always open to answer questions to a newly diagnosed patient who was afraid of the unknown, or to inspire hope in other patients who shared her plight of recurrent disease and who lost the desire to continue fighting their battle. Her magnetic personality, zest for life and ability to live life to the fullest even under the most challenging circumstances was contagious. On more than one occasion she told me, “Dad, it only takes one person to make a difference.” Over the years, her website www.alesecoco.org has received more then a quarter million visitors and to date her site remains heavily visited. Alese’s story of courage, hope and faith, coupled with her unending Fight 2 Win touched thousands of lives around the world. As her father, she taught me more about life in five years than I’d amassed the prior forty. She is my hero.

Even at a glance, the accomplishments of my fellow Board of Directors are jaw dropping. My wife—Alese's mother—Kathy and I are exceedingly grateful for the participation in this campaign. All these Directors knew Alese, they knew her passion for life and they understood her battle with Hodgkin’s. In her honor we move forward, and the leadership, talents and passion that each one of them brings to this campaign will make a difference in how this very misunderstood cancer is treated in the coming years.